SCHEMBL5363227

SCHEMBL5363227

O=C(O)c1cc(Cl)ccc1Oc1cc(F)cc(F)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPAS1 Q99814 5/20 0.60
PTGER4 P35408 3/20 0.50
GAA P10253 2/20 0.49
TSHR P16473 2/20 0.49
PTGER2 P43116 2/20 0.48
ALDH1A1 P00352 2/20 0.47
TP53 P04637 1/20 0.47
L3MBTL1 Q9Y468 3/20 0.47
POLB P06746 2/20 0.47
HPGD P15428 1/20 0.47
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
MRGPRX4 Q96LA9 2/20 0.44
SCN8A Q9UQD0 1/20 0.44
SCN10A Q9Y5Y9 1/20 0.44
LMNA P02545 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
NPSR1 Q6W5P4 1/20 0.44
CASP1 P29466 1/20 0.43
KDM4E B2RXH2 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4448975 0.88 PTGER4 (0.62) EPAS1PTGER4GAATSHRPTGER2
SCHEMBL4447285 0.87 PTGER4 (0.62) EPAS1PTGER4GAATSHRPTGER2
SCHEMBL11483350 0.85 EPAS1 (0.53) EPAS1PTGER4GAATSHRPTGER2
SCHEMBL5357450 0.84 EPAS1 (0.48) EPAS1PTGER4GAATSHRPTGER2
SCHEMBL5357850 0.84 EPAS1 (0.62) EPAS1PTGER4PTGER2SCN8ASCN10A
SCHEMBL11577659 0.83 GAA (0.54) PTGER4GAATSHRPTGER2ALDH1A1
SCHEMBL5357266 0.83 GAA (0.51) EPAS1PTGER4GAATSHRPTGER2
SCHEMBL22891351 0.82 CYP1A2 (0.57) GAATSHRALDH1A1TP53L3MBTL1
SCHEMBL11484213 0.81 MYC (0.49) EPAS1PTGER4GAATSHRPTGER2
SCHEMBL5363263 0.80 SCN8A (0.57) PTGER4GAATSHRPTGER2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1663979-B1 PHENYL OR PYRIDYL AMIDE COMPOUNDS AS PROSTAGLANDIN E2 ANTAGONISTS RAQUALIA PHARMA INC (JP) 2013-10-09 EP disclosed
US-7238714-B2 Aryl or heteroaryl amide compounds PFIZER JAPAN, INC. (JP) 2007-07-03 US disclosed
EP-1663979-A1 PHENYL OR PYRIDYL AMIDE COMPOUNDS AS PROSTAGLANDIN E2 ANTAGONISTS PFIZER INC. (US) 2006-06-07 EP disclosed
US-20050065188-A1 Aryl or heteroaryl amide compounds ASKAT INC. (JP) 2005-03-24 US disclosed
WO-2005021508-A1 PHENYL OR PYRIDYL AMIDE COMPOUNDS AS PROSTAGLANDIN E2 ANTAGONISTS PFIZER INC. (US) 2005-03-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050065188-A1 Aryl or heteroaryl amide compounds HRH2, PTGER1, LTB4R2 EPAS1 1007/4885PTGER4 13/4885GAA 2698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.